相关实验视频
Updated: Jan 17, 2026

10:34
A High-content Assay for Monitoring AMPA Receptor Trafficking
Published on: January 28, 2019
8.0K
在神经退行性疾病中的葡萄糖类-1受体激动剂:综合性审查
Ruba Ibrahim1, Aya Kambal1, Mohammed A Abdelmajeed1
1Medicine and Surgery, University of Medical Sciences and Technology (UMST), Khartoum, SDN.
Cureus
|September 18, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RA) 显示出作为阿尔茨海默氏症和帕金森氏症等神经退行性疾病的疾病修饰疗法的前景. 未来的研究旨在优化它们的使用,并开发透中枢神经系统的版本.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是一门学科.
背景情况:
- 神经退行性疾病 (NDs),包括阿尔茨海默氏症 (AD) 和帕金森氏症 (PD),代表着日益严重的全球健康挑战.
- 目前的治疗方法主要提供症状缓解,突出了疾病修饰疗法的必要性.
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 正成为一种潜在的疾病修饰策略.
研究的目的:
- 审查使用GLP-1RA治疗神经退行性疾病的机制论证和证据.
- 探索与GLP-1 RA疗法相关的多目标策略和翻译问题.
- 概述未来的研究议程,以优化ND中的GLP-1RA.
主要方法:
- 对GLP-1RA和神经退行性疾病现有研究的文献综述.
- 对支持GLP-1RA神经保护作用的机械数据的分析.
- 讨论转化挑战,包括治疗时间和副作用.
主要成果:
- 在神经退行性疾病中,GLP-1RA具有多重向潜力,对神经退行性疾病有益.
- 存在转化方面的挑战,特别是关于最佳治疗时间和中枢神经系统透.
- 潜在的副作用,如意外的体重减轻,需要在风险人群中仔细考虑.
结论:
- 对于患有神经退行性疾病的患者来说,GLP-1RA是一种有趣的多目标治疗选择.
- 进一步的研究对于优化临床试验GLP-1RA治疗方案至关重要.
- 开发具有增强中枢神经系统透力的进化激动剂和探索组合疗法的开发是未来的关键方向.
相关概念视频
Glucagon-like Receptor Agonists
850
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
850
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Treatment
987
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
987
Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.8K

